Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc C Chamberlain

Showing results (51-60 of 244) with videos related to

Pageof 25
Sort By:
Neurology|June 11, 2014
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationMarc C Chamberlain
Continuum (Minneapolis, Minn.)|February 5, 2015
Neoplastic myelopathiesMarc C Chamberlain
Continuum (Minneapolis, Minn.)|July 20, 2012
Patient Management ProblemMarc C Chamberlain
The Lancet. Oncology|August 1, 2012
Elderly people with glioblastomaMarc C Chamberlain
Expert Review of Neurotherapeutics|September 26, 2012
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case seriesMarc C Chamberlain
Journal of Neuro-Oncology|September 21, 2002
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomasMarc C Chamberlain
Cancer|September 5, 2002
Salvage chemotherapy for recurrent spinal cord ependymonaMarc C Chamberlain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccineMarc C Chamberlain
Journal of Neuro-Oncology|December 1, 2011
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningiomaMarc C Chamberlain
Neurology|February 25, 2009
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceMarc C Chamberlain
Pageof 25

Showing results (51-60 of 244) with videos related to

Sort By:
Pageof 25
Neurology|June 11, 2014
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationMarc C Chamberlain
Continuum (Minneapolis, Minn.)|February 5, 2015
Neoplastic myelopathiesMarc C Chamberlain
Continuum (Minneapolis, Minn.)|July 20, 2012
Patient Management ProblemMarc C Chamberlain
The Lancet. Oncology|August 1, 2012
Elderly people with glioblastomaMarc C Chamberlain
Expert Review of Neurotherapeutics|September 26, 2012
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case seriesMarc C Chamberlain
Journal of Neuro-Oncology|September 21, 2002
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomasMarc C Chamberlain
Cancer|September 5, 2002
Salvage chemotherapy for recurrent spinal cord ependymonaMarc C Chamberlain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccineMarc C Chamberlain
Journal of Neuro-Oncology|December 1, 2011
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningiomaMarc C Chamberlain
Neurology|February 25, 2009
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceMarc C Chamberlain
Pageof 25